Astellas Pharma Inc., of Tokyo, said it submitted a supplemental new drug application seeking approval of Tarceva (erlotinib) in first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have EGFR-activating mutations as detected by an approved test

Astellas Pharma Inc., of Tokyo, said it submitted a supplemental new drug application seeking approval of Tarceva (erlotinib) in first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have EGFR-activating mutations as detected by an approved test

Ironwood plans to initiate Phase I studies in healthy volunteers to assess the pharmacokinetics of IW-2143...Immune Pharmaceuticals Ltd., of Herzlyia-Pituach, Israel, and EpiCept Corp., of Tarrytown, N.Y., entered a merger agreement, anticipated to close in the first quarter of 2013, that will create a combined company – Immune Pharmaceuticals Inc. – focused on developing antibody therapeutics and other targeted drugs

Trials performed in animal models found that the distribution of lurbinectedin inside various types of tumor cells – pancreatic, ovarian and non-small-cell lung cancer – ruptures the DNA double-strand and induces apoptosis, significantly reducing the size of the tumor

Efficacy against non-small-cell lung cancer and pharmacokinetics also will be evaluated

In September, Peregrine reported positive data from a Phase IIb study of bavituximab plus docetaxel in non-small-cell lung cancer (NSCLC), though discrepancies between some patient sample test results and treatment code assignments later marred the findings

Ltd., for VAL-083, known as "DAG for injection" in China, where it's approved by the Chinese State Food and Drug Administration as a cancer chemotherapy for the treatment of chronic myelogenous leukemia and lung cancer

Pfizer Inc., of New York, said the European Commission gave conditional marketing authorization for Xalkori (crizotinib) for the treatment of adults with previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Eli Lilly and Co., of Indianapolis, said the FDA approved the label inclusion for Alimta (pemetrexed) with Phase III data demonstrating progression-free survival and overall survival advantages in the continuation maintenance setting for patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer following first-line Alimta plus cisplatin

Cancer Research UK, of London, reported Phase III data showing that elderly patients with advanced non-small-cell lung cancer who developed a rash within 28 days of receiving targeted therapy Tarceva (erlotinib, Roche AG and Astellas Pharma Inc.) survived an average of 6.2 months, compared to 4.1 months for patients who received placebo

Specialised Therapeutics Australia pty Ltd. (STA), of Melbourne, Australia, received exclusive commercialization rights to a ghrelin receptor agonist, anamorelin, for non-small-cell lung cancer cachexia-anorexia through an agreement with Helsinn Healthcare, of Lugano, Switzerland

Celgene Corp., of Summit, N.J., said the FDA approved Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for first-line treatment of locally advanced or metastatic non-small-cell lung cancer in combination with carboplatin for patients who are not candidates for curative surgery or radiation therapy...The lung cancer nod supported Celgene's 2010 acquisition of Abraxis BioScience Inc., which gave it rights to Abraxane, then approved only in breast cancer

The trial will evaluate three parallel cohorts of patients with small-cell lung cancer following a dose-escalation phase

The default stemmed from the discovery of major discrepancies in the firm's Phase II study of bavituximab in second-line non-small-cell lung cancer, marring its previously reported positive top-line results

Boehringer Ingelheim GmbH, of Ingelheim, Germany, said it submitted a marketing authorization application to the European Medicines Agency for approval of afatinib, an irreversible ErbB family blocker, as a treatment for patients with EGFR mutation-positive non-small-cell lung cancer

Boehringer Ingelheim GmbH, of Ingelheim, Germany, said it submitted a marketing authorization application to the European Medicines Agency for approval of afatinib, an irreversible ErbB family blocker, as a treatment for patients with EGFR mutation-positive non-small-cell lung cancer

Merck KGgA, of Darmstadt, Germany, said it withdrew its application from the European Medicines Agency seeking to extend the use of cancer drug Erbitux (cetuximab) in non-small-cell lung cancer

expanded access program for investigational oncology compound afatinib, which will be available to eligible patients with locally advanced or metastatic non-small-cell lung cancer who have an epidermal growth factor receptor mutation

expanded access program for investigational oncology compound afatinib, which will be available to eligible patients with locally advanced or metastatic non-small-cell lung cancer who have an epidermal growth factor receptor mutation